Charles Michaud
No más puestos en curso
Fortuna: 26 178 $ al 30/04/2024
Origen de la red de primer grado Charles Michaud.
| Entidad | Tipo de entidad | Industria | |
|---|---|---|---|
AOBiome Therapeutics, Inc.
 AOBiome Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology AOBiome Therapeutics, Inc. develops microbiome-targeted therapies for local, nasal and systemic inflammatory conditions. Its portfolio includes three clinical-stage programs, a Phase 2b study to treat patients with acne vulgaris, a Phase 2 trial to reduce elevated blood pressure, and a Phase 1b/2a clinical trial in allergic rhinitis, as well as earlier-stage preclinical programs targeting diverse inflammatory indications. The company was founded by Jamie Heywood, David Whitlock and Lenny Barshack in 2013 and is headquartered in Cambridge, MA.
1
| Holding Company | Pharmaceuticals: Major | 1 |
Gráfico Empresas conectadas de segundo grado
Relaciones con varias empresas
Empresas conectadas a Charles Michaud a través de su red personal
| Empresa | Sector | Personas relacionadas | Puesto principal |
|---|---|---|---|
| Massachusetts Institute of Technology | College/University | Undergraduate Degree | |
McKinsey & Co., Inc.
 McKinsey & Co., Inc. Miscellaneous Commercial ServicesCommercial Services McKinsey & Co., Inc. provides management consulting services. It specializes in design, marketing and sales, analytics, operations, transformation and restructuring, risk, strategy and corporate finance, and sustainability and resource productivity. The company was founded by James O. McKinsey in 1926 and is headquartered in New York, NY. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
| AMGEN INC. | Pharmaceuticals: Major | Corporate Officer/Principal | |
| RELYPSA INC | Pharmaceuticals: Major | Director/Board Member | |
| DYNAVAX TECHNOLOGIES CORPORATION | Biotechnology | Director of Finance/CFO | |
| UCLA Anderson School of Management | College/University | Masters Business Admin | |
| SYNLOGIC, INC. | Biotechnology | Chief Operating Officer | |
| CYTEIR THERAPEUTICS, INC. | Biotechnology | Corporate Officer/Principal | |
| ATHIRA PHARMA, INC. | Biotechnology | Director of Finance/CFO | |
Turn Therapeutics(TM), Inc
 Turn Therapeutics(TM), Inc Medical SpecialtiesHealth Technology Turn Therapeutics(TM), Inc is a pharmaceutical and medical device organization that aims to reduce the human and economic costs of infection and skin disease. Turn Therapeutics(TM is based in Calabasas, CA. The private company's core mission is to innovate and educate in order to render disease obsolete. The company has multiple, mass market-ready, proprietary assets incorporating advanced delivery and healing technologies, including their FDA cleared product, Hexagen® wound dressing, which is non-irritating, non-cytotoxic, and non-sensitizing, as well as suitable for extended-wear. The company was founded by Bradley Burnam, who has been the CEO since incorporation. | Medical Specialties | Director/Board Member |
Estadísticas
Internacional
| Estados Unidos | 15 |
Sectorial
| Health Technology | 12 |
| Finance | 2 |
| Commercial Services | 2 |
| Consumer Services | 2 |
Operativa
| Director/Board Member | 5 |
| Corporate Officer/Principal | 5 |
| Director of Finance/CFO | 3 |
| Chief Executive Officer | 2 |
| President | 2 |
Las relaciones más conectadas
| Insiders | |
|---|---|
| Andrew Gengos | 15 |
- Bolsa de valores
- Insiders
- Charles Michaud
- Conexiones Empresas